Sponsors

Coeliac disease: boosting research efforts

The independent charity Coeliac UK has launched a research fund and accompanying fundraising appeal, which aims to raise £5 million to change the future for people with coeliac disease and gluten-related autoimmune conditions. It will boost research efforts into key areas identified and agreed by patients, carers and healthcare professionals.

With the charity celebrating its 50th anniversary this year, there is a greater urgency to find better answers to the disease, which has links to other autoimmune conditions such as type 1 diabetes and autoimmune thyroid disease, and still relies on the gluten-free diet as its only treatment.

Sarah Sleet, chief executive of Coeliac UK, said: “It is possible through further research, that finding the answers to coeliac disease could enable answers to other devastating autoimmune conditions such as type 1 diabetes. With more people being diagnosed with coeliac disease each year and with new health complications emerging, it is critical that we make the commitment now to change the status quo and make coeliac disease research everyone’s priority.”

A video was produced as part of the appeal launch to show the impact of the disease on those affected. The video, which can be accessed via the link below, shows the various presentations of coeliac disease including refractory coeliac disease type 2 (which is not responsive to the gluten-free diet), osteoporosis and gluten ataxia.

www.coeliac.org.uk/researchfund

Latest Issues

ECP 2026 - 38th European Congress of Pathology

Stockholmsmässan, Stockholm, Sweden
12-16 September, 2026

UK NEQAS Parasitology Symposium

UKHSA, 61 Colindale Avenue, London NW9 5EQ
18 September, 2026

UKHSA Conference 2026

Manchester Central, Manchester, M2 3GX
22-23 September, 2026

Cardiac Marker Dialogues

Technology and Innovation Centre, University of Strathclyde, 99 George Street, Glasgow, G1 1RD
24-25 September, 2026

46th European Congress of Cytology

Hilton Antwerp Old Town, Antwerp
4-7 October, 2026